使用人工智能来学习阿尔茨海默病的最佳治疗方案计划
Kritib Bhattarai1, Sivaraman Rajaganapathy2, Trisha Das3
1Luther College, Decorah, Iowa, USA.
概括
这项研究使用了强化学习 (RL) 来分析阿尔茨海默病 (AD) 患者的电子健康记录. RL模型显示出创造最佳治疗计划的潜力,特别是在患有高血压和抑郁症等并发症的患者中.
科学领域:
- 人工智能的人工智能
- 计算神经科学是一种神经科学.
- 医疗信息学 医疗信息学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经系统疾病,没有治愈方法.
- 管理AD患者需要复杂的临床技能,因为经常出现并发症.
- 优化阿兹海默症患者与同时存在的疾病治疗方案是具有挑战性的.
研究的目的:
- 为了利用强化学习 (RL) 来学习AD患者的临床决策.
- 开发一种基于RL的方法,利用纵向电子健康记录 (EHR) 数据优化治疗方案.
- 与临床医生的决定相比,评估RL产生的治疗政策的性能.
主要方法:
- 利用了阿尔茨海默病神经成像计划 (ADNI) 数据库中的1736名患者的数据.
- 根据AD,高血压和抑郁状态创建了五个数据队列.
- 模拟治疗选择作为RL问题,具有定义的状态,行动 (药物组合) 和奖励 (MMSE得分).
主要成果:
- RL模型证明了产生最佳治疗政策的能力.
- 与临床医生政策相比,最佳政策 (政策代,Q学习) 在较大的数据集上表现更好.
- 性能因数据集大小而异,RL在更大的数据集上表现优于临床医生.
结论:
- 强化学习具有显著的潜力,可以从纵向患者数据中生成最佳的AD治疗计划.
- 这项研究为基于RL的决策支持系统铺平了道路,以帮助管理AD与并发症.
- 在复杂的患者群体中,RL可以增强临床决策.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.这就是Q-learning.行动行动行动行动行动行动政策 政策 政策 政策政策代 政策代强化学习是一种强化学习.奖励 奖励 奖励 奖励 奖励学习 治疗 治疗 学习更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.2K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
相关概念视频
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:24Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
158
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
158